Panag Pharma Inc., a subsidiary of Tetra Bio-Pharma Inc., today announced completion of Panag 001, its Phase 3 clinical trial evaluating the safety and efficacy of Topical-A, now branded as Awaye™ for the treatment of pain caused by osteoarthritis of the knee.
Tetra Bio-Pharma Inc. today announced the retirement of Bernard Lessard as Chief Financial Officer and the appointment of Sabino Di Paola as his replacement effective May 15.
OTTAWA, May 09, 2019 (GLOBE NEWSWIRE) -- PANAG Pharma Inc. (PANAG), a wholly owned subsidiary of Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), a bio-pharmaceutical company engaged in…
Tetra Bio-Pharma Inc. is pleased to announce that it completed today the previously-announced acquisition of Panag Pharma Inc. pursuant to a share purchase agreement dated January 30, 2019 between the Company and the shareholders of Panag.
Tetra Bio-Pharma Inc. and Altus Formulation Inc. today announced the signing of a Joint Venture Agreement under which the two companies will work together to develop a series of cannabinoid-receptor targeted therapeutics addressing multiple areas of high unmet need.
Tetra Bio-Pharma Inc. is pleased to announce that, at a special meeting of shareholders held today, the shareholders of the Company voted in favor of an ordinary resolution to approve the previously announced acquisition of Panag Pharma Inc.
Tetra Bio-Pharma Inc. today announced that it has entered into a collaboration agreement with Ovensa Inc. to evaluate TRIOZANTM, a proprietary nanomedicine platform for targeted delivery of cannabinoids to brain tumor cells.
Tetra Bio-Pharma Inc. today announced that the Company has renewed its CEO Guy Chamberland’s employment agreement.
Tetra Bio-Pharma Inc. today announced it is ready to submit its PPP001 cannabinoid-derived drug as a herbal medicinal product to the European Medicines Agency.
Tetra Bio-Pharma Inc. today announced the promotion of Aurelia De Pauw to Vice-President, Clinical Programs and Medical Affairs. In her new role Dr. De Pauw will be responsible for of all clinical operations and relations with the medical community, building Tetra Bio-Pharma’s clinical department and ensuring it continues to meet the highest standards of a pharmaceutical company.